Insider · fund or company
Olymbec Investments Inc.
Olymbec Investments Inc. has reported about $43.6M in shares of Cannara Biotech Inc on SEDI, Canada's insider filing system. That is #205 among the insiders we track.
Holdings as of November 17, 2026 · 10% holder
Disclosed holdings
$43.6M
Companies
1
Buys / sells (12 months)
1 / 0
Net bought (12 months)
+$97K
About these filings
Directors, officers and large shareholders of Canadian-listed companies must report their trades on SEDI, usually within five days. A filing shows what they did with their own shares, not why: people buy and sell for many reasons, including taxes, diversification and option exercises. The data here is a record of those filings and what the stocks did afterwards, not a recommendation.
Follow Olymbec Investments Inc.
Get an email when they file a new trade on SEDI. Free, with the Wealth Awesome newsletter.
Holdings by company
Latest balance reported on SEDI for each company (direct and through holding companies), valued at the latest close.
| Company | Role | Shares | Value | Last filing |
|---|---|---|---|---|
| Cannara Biotech IncLOVE.V · all insiders | 10% holder | 23,842,920 | $43.6M | 2026-07-29 |
Track record after buying
Every open-market buy since 2016, and what the stock did 3, 6 and 12 months later (adjusted closes; same-day buys of one stock count once; each return capped at +300%). Ranked #90 on the insider track record.
Buys
30
Avg after 3 months
+0.4%
Avg after 6 months
+3.8%
Avg after 12 months
+50.8%
Up after 1 year
67% of 27
| Date | Company | Bought | 3 mo | 6 mo | 12 mo |
|---|---|---|---|---|---|
| 2026-07-29 | Cannara Biotech IncLOVE.V | $97K | not yet | not yet | not yet |
| 2025-05-06 | Cannara Biotech IncLOVE.V | $350K | +39.9% | +18.1% | not yet |
| 2025-05-01 | Cannara Biotech IncLOVE.V | $138K | +22.2% | +15.3% | not yet |
| 2025-01-31 | Cannara Biotech IncLOVE.V | $14K | +30.3% | +72.5% | +57.8% |
| 2024-11-29 | Cannara Biotech IncLOVE.V | $15K | +74.7% | +59.5% | +107.6% |
| 2024-11-28 | Cannara Biotech IncLOVE.V | $15K | +84.0% | +69.3% | +125.3% |
| 2024-08-21 | Cannara Biotech IncLOVE.V | $92K | −13.0% | +55.8% | +142.9% |
| 2024-08-15 | Cannara Biotech IncLOVE.V | $44K | −14.3% | +80.0% | +172.9% |
| 2024-07-26 | Cannara Biotech IncLOVE.V | $30K | +4.7% | +32.8% | +179.7% |
| 2024-05-21 | Cannara Biotech IncLOVE.V | $5K | −18.5% | −27.2% | +56.8% |
| 2024-05-17 | Cannara Biotech IncLOVE.V | $8K | −16.0% | −24.7% | +63.0% |
| 2024-05-16 | Cannara Biotech IncLOVE.V | $8K | −12.5% | −25.0% | +63.8% |
| 2024-05-15 | Cannara Biotech IncLOVE.V | $5K | −18.2% | −18.2% | +66.2% |
| 2024-05-14 | Cannara Biotech IncLOVE.V | $5K | −22.1% | −22.1% | +64.9% |
| 2024-05-13 | Cannara Biotech IncLOVE.V | $5K | −19.8% | −23.5% | +65.4% |
| 2024-05-10 | Cannara Biotech IncLOVE.V | $16K | −11.5% | −15.4% | +70.5% |
| 2024-05-09 | Cannara Biotech IncLOVE.V | $4K | −11.5% | −12.8% | +69.2% |
| 2024-05-08 | Cannara Biotech IncLOVE.V | $4K | −16.2% | −12.2% | +81.1% |
| 2024-05-07 | Cannara Biotech IncLOVE.V | $5K | −18.4% | −1.3% | +71.1% |
| 2024-02-29 | Cannara Biotech IncLOVE.V | $50K | −24.5% | −26.5% | +40.8% |
| 2024-02-27 | Cannara Biotech IncLOVE.V | $48K | −27.0% | −36.0% | +29.0% |
| 2023-05-31 | Cannara Biotech IncLOVE.V | $74K | +0.0% | −12.6% | −22.1% |
| 2023-05-30 | Cannara Biotech IncLOVE.V | $78K | +0.0% | −7.4% | −22.1% |
| 2023-05-29 | Cannara Biotech IncLOVE.V | $11K | +0.0% | −7.4% | −23.2% |
| 2023-05-26 | Cannara Biotech IncLOVE.V | $425 | +0.0% | −5.3% | −21.1% |
Showing the latest 25 of 30 buys.
Recent insider filings
| Date | Company | Type | Shares | Price | Balance after |
|---|---|---|---|---|---|
| 2026-07-29 | Cannara Biotech IncCommon Shares | Buy | 50,000 | $1.93 | 23,842,920 |
| 2025-10-01 | Cannara Biotech IncConvertible Debentures | Conversion or exchange | — | — | — |
| 2025-10-01 | Cannara Biotech IncCommon Shares | Conversion or exchange | 3,462,763 | $1.80 | 23,792,920 |
| 2025-05-06 | Cannara Biotech IncCommon Shares | Buy | 250,000 | $1.40 | 20,330,157 |
| 2025-05-01 | Cannara Biotech IncCommon Shares | Buy | 97,900 | $1.41 | 20,080,157 |
| 2025-01-31 | Cannara Biotech IncCommon Shares | Buy | 12,500 | $1.08 | 19,982,257 |
| 2024-11-29 | Cannara Biotech IncCommon Shares | Buy | 19,000 | $0.771 | 19,969,757 |
| 2024-11-28 | Cannara Biotech IncCommon Shares | Buy | 21,000 | $0.737 | 19,950,757 |
| 2024-08-21 | Cannara Biotech IncCommon Shares | Buy | 120,500 | $0.764 | 19,929,757 |
| 2024-08-15 | Cannara Biotech IncCommon Shares | Buy | 63,500 | $0.688 | 19,809,257 |
| 2024-07-26 | Cannara Biotech IncCommon Shares | Buy | 48,000 | $0.626 | 19,745,757 |
| 2024-05-21 | Cannara Biotech IncCommon Shares | Buy | 6,000 | $0.820 | 19,697,757 |
| 2024-05-17 | Cannara Biotech IncCommon Shares | Buy | 10,000 | $0.821 | 19,691,757 |
| 2024-05-16 | Cannara Biotech IncCommon Shares | Buy | 10,000 | $0.801 | 19,681,757 |
| 2024-05-15 | Cannara Biotech IncCommon Shares | Buy | 6,000 | $0.790 | 19,671,757 |
| 2024-05-14 | Cannara Biotech IncCommon Shares | Buy | 6,000 | $0.779 | 19,665,757 |
| 2024-05-13 | Cannara Biotech IncCommon Shares | Buy | 6,000 | $0.798 | 19,659,757 |
| 2024-05-10 | Cannara Biotech IncCommon Shares | Buy | 21,000 | $0.781 | 19,653,757 |
| 2024-05-09 | Cannara Biotech IncCommon Shares | Buy | 6,000 | $0.730 | 19,632,757 |
| 2024-05-08 | Cannara Biotech IncCommon Shares | Buy | 6,000 | $0.747 | 19,626,757 |
| 2024-05-07 | Cannara Biotech IncCommon Shares | Buy | 6,000 | $0.760 | 19,620,757 |
| 2024-02-29 | Cannara Biotech IncCommon Shares | Buy | 50,000 | $1.000 | 19,614,757 |
| 2024-02-27 | Cannara Biotech IncCommon Shares | Buy | 50,000 | $0.954 | 19,564,757 |
| 2023-05-31 | Cannara Biotech IncCommon Shares | Buy | 66,000 | $1.13 | 19,514,757 |
| 2023-05-30 | Cannara Biotech IncCommon Shares | Buy | 61,000 | $1.00 | 19,448,757 |
| 2023-05-30 | Cannara Biotech IncCommon Shares | Buy | 2,000 | $0.990 | 19,387,757 |
| 2023-05-30 | Cannara Biotech IncCommon Shares | Buy | 10,000 | $0.980 | 19,385,757 |
| 2023-05-30 | Cannara Biotech IncCommon Shares | Buy | 500 | $0.960 | 19,375,757 |
| 2023-05-30 | Cannara Biotech IncCommon Shares | Buy | 5,000 | $0.950 | 19,375,257 |
| 2023-05-30 | Cannara Biotech IncCommon Shares | Buy | 500 | $0.930 | 19,370,257 |
| 2023-05-29 | Cannara Biotech IncCommon Shares | Buy | 2,000 | $0.940 | 19,369,757 |
| 2023-05-29 | Cannara Biotech IncCommon Shares | Buy | 2,500 | $0.920 | 19,367,757 |
| 2023-05-29 | Cannara Biotech IncCommon Shares | Buy | 7,500 | $0.900 | 19,365,257 |
| 2023-05-26 | Cannara Biotech IncCommon Shares | Buy | 500 | $0.850 | 19,357,757 |
| 2023-05-25 | Cannara Biotech IncCommon Shares | Buy | 12,500 | $0.850 | 19,357,257 |
| 2023-05-24 | Cannara Biotech IncCommon Shares | Buy | 2,000 | $0.850 | 19,344,757 |
| 2023-05-19 | Cannara Biotech IncCommon Shares | Buy | 6,000 | $0.880 | 19,342,757 |
| 2023-05-18 | Cannara Biotech IncCommon Shares | Buy | 6,025 | $0.850 | 19,336,757 |
| 2023-02-13 | Cannara Biotech IncCommon Shares | Buy | 10,300 | $0.990 | 19,330,732 |
| 2023-02-13 | Cannara Biotech IncCommon Shares | Stock split or consolidation | -173,883,891 | — | 19,320,432 |
Free with a Wealth Awesome account
Keep analysing Olymbec Investments Inc., free
- Every WA Score, ranking and table
- Insider track records and SEDI filings
- Earnings history and analyst targets for every stock
Email only, no password, no card. Already a member? Use the same button to sign in.
How we count it: for each company we take the latest share balance Olymbec Investments Inc. reported on SEDI for common-type shares (held directly or through holding companies) and value it at the latest close. Options, warrants and share units are left out, and so are balances with no filing in the last three years (insiders stop reporting when they leave the role). This is not a net worth figure: it covers only Canadian-listed shares reported on SEDI, and balances can lag until the next filing.
Canada's biggest insider shareholders · Latest insider trades
Awesome Portfolio™
Our 10 best Canadian stocks, in one list.
14.8% a year since 2017 against 9.7% for the S&P/TSX Composite (+5.0 points a year). Reviewed every month.
